Abstract:
Ganoderma lucidum (Reshi or Ling Zhi) has been used in traditional Chinese medicine (TCM) as an anti-tumor and immunomodulating agent. The present disclosure relates to the discovery of methods of isolating certain novel constituents of Reishi extract, and of subsequent administration of these novel isolates to eukaryotic cells in order to induce certain immumodulatory, hematopoietic and tumor-inhibiting phenotypic changes in those eukaryotic cells, mediated through particular toll-like receptors (TLR) and other transmembrane receptors.
Fields of Application:
Vaccine adjuvants, particularly, for oral vaccine and anti-cancer drug adjuvants, modulating immune and intestinal function.
Advantages when compared to the existing technologies:
At present, the known agonist of TLR5 is flagellin which is a protein. Our agonist of TLR5 obtained from Reishi consists of polysaccharides which is novel.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
IP Status:US pending
